Company*
(Country;
Symbol)		 Company*
(Country;
Symbol)		 Type/Product Area Terms/Details (Date)
Advanced Cell
Technology Inc.
(OTC BB:ACTC)		 Infigen Inc.* Agreement for intellectual property assets of Infigen relating to somatic cell nuclear transfer, parthenogenesis and related technologies A total of 26 issued patents and a number of patent applications were acquired for an undisclosed amount of cash and stock (2/8)
Affinium
Pharmaceuticals
Inc.* (Canada)		 Accium BioSciences Inc.* Agreement under which Accium will provide regulatory and analytical services under a U.S. biodefense grant Affinium has a $4.8M contract from the U.S. Defense Threat Reduction Agency to develop antibiotics for treating diseases caused by serious pathogens (2/12)
Affymetrix
Inc. (AFFX)		 Tessarae Inc.* Nonexclusive access agreement for Affymetrix's micro-array technology to develop and market epidemiological research tests for public health and biodefense surveillance The TessArray kits are designed to detect hundreds of strains of natural and emergent viral and bacterial pathogens, as well as biothreat agents (1/23)
Agilent
Technologies
Inc. (NYSE:A) 		Lipomics
Technologies
Inc.		 Collaboration to develop research and diagnostic assays combining Agilent's analytical platforms with Lipomics' expertise in biomarker discovery and validation The assays will focus on metabolic diseases; terms were not disclosed (2/12)
Aileron
Therapeutics
Inc.*		 Materia Inc.* Licensing agreement for a metathesis platform from Materia for use in the discovery and development of peptide therapeutics directed at intracellular protein-protein interaction targets Materia will be entitled to license fees, milestone payments and royalties (2/12)
Algynomics
Inc.*		 Orthogen AG*
(Germany)		 Alliance in the area of individualized orthopedic medicine They plan to facilitate clinical studies designed to identify genetic markers of orthopedic diseases and responses to pharmacological and nonpharmacological treatments (2/5)
Alkermes Inc.
(ALKS)		 Indevus
Pharmaceuticals
Inc. (IDEV)		 Deal to develop ALKS 27, an inhaled formulation of trospium chloride for treating chronic obstructive pulmonary disease They will shares costs and any returns from the product, which has completed Phase I trials; they intend to partner it after Phase IIa trials; ALKS 27 contains technology from each company (1/4)
Altus
Pharmaceuticals
Inc. (ALTU)		 Genentech Inc.
(NYSE:DNA)		 Deal to develop and market Altus' ALTU-238, a formulation of human growth hormone; the deal covers North America, with a global option Altus gets a $15M up-front payment and a $15M equity investment; it could get up to $140M more in development and commercialization milestones, and up to $110M more in up-front and milestone payments if Genentech options global rights; Altus would get double-digit royalties on sales (12/20)
Amgen Inc.
(AMGN) 		InteKrin
Therapeutics
Inc.*		 InteKrin got worldwide rights to a PPAR gamma selective modulator and partial agonist, INT131 (AMG131) The insulin sensitizer, first developed by Tularik Inc., is in Phase II trials; terms of the deal were not disclosed (1/10)
Amphora
Discovery
Corp.*		 Genentech Inc.
(NYSE:DNA)		 Genentech is acquiring an Amphora program targeting an undisclosed cancer target Genentech acquired a preclinical lead and backup series; terms of the deal were not disclosed (1/9)
Amylin
Pharmaceuticals
Inc. (AMLN)		 PsychoGenics
Inc.*		 Agreement to form Psylin Neurosciences Inc., which will be owned by both companies on a 50- 0 basis Psylin will focus on discovering and developing peptide hormones against psychiatric disorders using compounds from Amylin's Phormol polypeptide hormone library combined with PsychoGenics' drug discovery technologies (1/30)
Applied DNA
Sciences Inc.
(OTC BB:APDN)		 PHRI Properties* Agreement for molecular beacons technology Applied DNA will incorporate the beacons in its next generation of instant detection devices (2/8)
Ariad
Pharmaceuticals
Inc. (ARIA)		 CellNexus LLC* Nonexclusive agreement to use Ariad's Argent cell-signaling regulation technology to develop cancer therapies Ariad gained an equity stake in newly formed CellNexus, and is eligible to receive milestone payments (2/12)
ArQule Inc.
(ARQL)		 Boston Biomedical
Inc.*		 Sponsored research agreement Deal is worth $5M and involves scientific research over eight months to study mechanisms of action and biomarkers for ArQule's lead products (1/29)
aOvaTechnol-
ogies Inc.*		 Cytochroma
Inc.* (Canada)		 Cytochroma got rights to develop aOva technology for hyperphosphatemia in patients with chronic kidney disease aOva gets an up-front license fee and would get royalties on resulting sales (1/8)
AureoGen
Biosciences Inc.*		 Takara Bio Inc.
(Japan; PK:TKBIF)		 License agreement providing AureoGen access to several antibiotic compounds, as well as an organism that produces a potentially potent antifungal compound AureoGen plans to genetically alter the genome in Takara's antifungal-producing organism to produce novel broad-spectrum drug candidates (1/30)
Avant Immuno-
therapeutics Inc.
(AVAN)		 Select Vaccines
Ltd. (Australia;
BE:R4Z)		 Collaboration to use Select Vaccines' virus-like particles as a platform technology for development of viral vaccines Avant will make an equity investment in Select Vaccines and fund research and development for two years; Select Vaccines also is eligible to receive preclinical and clinical milestone payments, as well as royalties on any resulting sales (2/12)
AVI
BioPharma
Inc. (AVII)		 Eleos Inc.* They entered a cross-license deal for development of antisense drugs targeting p53 Eleos got rights to technology for treating cancer with p53-related drugs; AVI got rights in viral diseases; they will share rights in other indications; AVI got $0.5M up front in the deal (1/9)
AVI
BioPharma
Inc. (AVII)		 Ercole Biotech
Inc.*		 Cross-license and collaboration deal to identify and develop drugs that direct the splicing of mRNA, for treating various diseases Each is granting the other rights under respective patents for RNA splice-altering technologies; each also is getting equity in the other; further terms were not disclosed (12/20)
BG Medicine
Inc.*		 Applied
Biosystems
Group
(NYSE:ABI)		 Collaboration focused on enhancing biomarker discovery and development BG will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore applications for Applied Biosystems' genomic tools over the next two years (1/16)
BioAxone
Therapeutic
Inc.* (Canada)		 Boston Life
Sciences Inc.
(BLSI)		 BLSI got worldwide rights to Cethrin and other compounds for treating acute spinal cord injury and other CNS disorders BioAxone gets an up-front fee and is eligible to receive milestone and royalty payments; Cethrin, designed to facilitate the regrowth of axons, has completed a Phase I/IIa trial (1/4)
BioInvent
International AB
(Sweden)		 Genentech
Inc. (NYSE:DNA)		 Deal to co-develop BioInvent's preclinical monoclonal antibody BI-204 for the prevention of acute coronary syndrome BioInvent received $15 million and is eligible for up to $175 million in milestone payments; companies will share development costs; Genentech has commercial rights to BI-204 in North America (1/12)
Biotecnol SA*
(Portugal)		 Peregrine
Pharmaceuticals
Inc. (PPHM)		 Deal to develop targeted immunocytokine agents for treating cancer and other diseases They will use Peregrine's vascular-targeting agent platform and Biotecnol's Tribody technology in the effort; Peregrine can get rights to resulting agents; terms were not disclosed (12/14)
BioWa Inc.
(subsidiary of
Kyowa Hakko
Kogyo Co. Ltd.;
Japan; FSE:KY4)		 UCB SA
(Belgium;
FSE:UNC)		 Access agreement for BioWa's Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies UCB got nonexclusive rights to research and develop antibodies for an undisclosed number of targets; BioWa gets license fees along with potential milestone and royalty payments (2/5)
Chromos
Molecular
Systems Inc.
(Canada; TSX:CHR)		 Genitope Corp.
(GTOP)		 Cell line engineering service agreement Companies will develop a cell line using Chromos' ACE System for the expression of a monoclonal antibody (1/12)
CODA
Genomics
Inc.*		 Integrated
Genomics Inc.*		 Deal to apply CODA's Translation Engineering protein expression technology to an IGI expression system CODA is applying the technology to thePichia yeast expression system, in an effort to improve yields; terms were not disclosed (1/4)
CODA
Genomics
Inc.*		 Viventia Biotech
Inc.* (Canada)		 They expanded deal under which CODA is applying technology to antibody programs at Viventia CODA is applying its Translational Engin- eering protein expression technology in the deal; terms were not disclosed (12/19)
CollaGenex
Pharmaceuticals
Inc. (CGPI)		 MediGene
AG (Germany;
FSE:MDG)		 MediGene got rights to the rosacea drug Oracea in the European Union, certain other countries and Russia CollaGenex gets $5M up front and up to $7.5M in sales milestones; it also would get royalties of 12% to 15%; European approval was expected in 2007 (12/20)
Compugen
Ltd. (CGEN)		 Medarex Inc.
(MEDX)		 Preclinical deal to create therapeutics for cancer and autoimmune diseases Compugen will work to identify new drug targets, against which Medarex will develop fully human antibodies; companies will share responsibilities and revenues (1/23)
Critical
Therapeutics
Inc.*		 Innovative
Metabolics Inc.*		 Exclusive worldwide license agreement to patent rights for medical device approaches to stimulating the vagus nerve Critical Therapeutics will receive an initial license fee of $500,000 in cash plus an unspecified number of preferred shares, as well as a $1M milestone payment and royalties (1/30)
Crucell NV
(the Netherlands;
CRXL) and DSM
Biologics (the
Netherlands)		 AbGenomics
Corp.* (Taiwan)		 AbGenomics got certain rights to use the PER.C6 cell line for preclinical and early clinical development of monoclonal antibodies AbGenomics will make license payments and pay annual maintenance fees; further terms were not disclosed (1/11)
Crucell NV
(the Netherlands;
CRXL) and DSM
Biologics (the
Netherlands)		 Biotecnol SA* Biotecnol got rights to use the PER.C6 human cell line for preclinical and Phase I development of its antibody products Biotecnol will make license payments and provide annual maintenance fees; further terms were not disclosed (1/5)
Cytokinetics
Inc. (CYTK)		 Amgen Inc.
(AMGN)		 Deal to develop small-molecule therapeutics that activate cardiac muscle contractility for treating heart failure; Amgen also got rights to the lead agent in the program, the Phase I product CK- 827452 Cytokinetics gets up-front license and technology-access fees of $42M; Amgen also purchased 3.485M Cytokinetics shares for $33M; it would get $50M if Amgen exercises its option on CK-1827452; and it also could get up to$600M in milestone payments, as well as royalties on sales (1/3)
Cytokine
PharmaSciences
Inc.*		 Presidio
Pharmaceuticals
Inc.*		 Presidio got rights to a series of preclinical-stage compounds for treating HIV infection The deal also includes NEXT, or nuclear exclusion technology; terms were not disclosed (1/9)
DanioLabs Ltd.*
(UK)		 Senexis Ltd.* (UK) Collaboration focused on discovering new treatments for aging-related diseases Companies plan to combine their two approaches to try to develop molecules that can be disease-modifying therapies of Alzheimer's disease (1/24)**
DelSite
Biotechnologies
Inc. (subsidiary
of Carrington
Laboratories Inc.;
CARN)		 AriaVax Inc.*
GelSite polymer
delivery
technology		 Nonexclusive license agreement to develop and evaluate a vaccine against HIV infection using DelSite's The objective is to create a peptide vaccine formulation that will enhance the immune system and remain stable at room temperature (2/1)
DelSite
Biotechnologies
Inc. (subsidiary
of Carrington
Laboratories Inc.;
CARN)		 ElSohly
Laboratories Inc.*		 Technology license agreement covering the use of GelSite polymer technology in formulating an anticancer drug ElSohly expects the polymer to enhance the solubility and extend the release time of its lead drug candidate and analogs currently under development (2/20)
Depomed Inc.
(DEPO)		 Biovail Corp.
(Canada;
NYSE:BVF)		 Agreement to access Depo-med's drug delivery technology to develop up to two products Biovail will select the products from an agreed- pon list of compounds over the next 18 months; Depomed received a $500,000 up-front fee and will have no development obligations; Biovail also will make milestone and royalty payments (2/12)
DOV
Pharmaceuticals
Inc. (DOVP)		 XTL Biopharma-
ceuticals Ltd.
(Israel; XTLB)		 XTL gains rights to the late-
stage pain drug, bicifadine		 The deal is potentially worth more than $130M, including a $7.5M up-front fee and up to$126.5M in milestone payments, plus escalating low double-digit royalties on product sales (1/16)
Elbion SA *
(Belgium)		 DrugAbuse
Sciences* (France)		 Elbion acquired a sustained-
release formulation of
naltrexone		 Naltrexone Depot, designed as a once-a- month intramuscular injection, is expected to enter pivotal Phase III trials for treating alcohol abuse in 2007 (1/24)**
Elixir
Pharmaceuticals
Inc.*		 Siena Biotech SpA* (Italy) Collaboration on the opti-
mization, calidation and
evaluation of Elixir's SIRTI
inhibitors in Huntington's
disease		 Elixir will provide the inhibitors and Siena may modify the compounds; Elixir will own rights to the new compounds for use in all disease areas, excluding neurodegenerat- ive diseases, for which Siena will have the right to an exclusive license (2/14)
EpiCept
Corp. (EPCT)		 Durect Corp.
(DRRX)		 Durect got worldwide rights
to EpiCept technology for a
transdermal patch containing
bupivacaine, for treating back
pain		 EpiCept gets $1M up front, and up to $9M in milestone payments, as well as certain roy- alty payments on sales (12/26)
Epidauros
Biotechnologie
AG* (Germany)		 Osmetech plc*
(UK; LSE:OMH)		 Deal to develop pharmaceutical
companion diagnostics and
molecular diagnostic products		 The deal covers companion diagnostics for new and existing pharmaceuticals, as well as pharmacogenomic biomarkers (1/9)
Epitome Biosystems* EMD Biosciences
Inc.*		 Collaboration to develop
multiplex assays to measure
phosphorylation of cell
signaling proteins using
EpiTag technology		 Products resulting will be manufactured, marketed and sold for research applications on a worldwide basis by EMD (1/31)
Exelixis Inc.
(EXEL)		 Genentech Inc.
(NYSE:DNA)		 Deal to develop Exelixis' XL518,
a small-molecule inhibitor of
MEK, for treating cancers; an
IND for clinical trials was
submitted in December		 Exelixis gets up-front and milestone pay- ments totaling $40M upon the deal's signing and the IND submission; it is entitled to additional payments, and royalties on sales; Exelixis also retained a co-promotion option in the U.S. (1/3)
Galapagos NV
(Belgium;
Euronext: GLPG)		 Hillcrest
Therapeutics
Inc.*		 Agreement for worldwide
rights to develop PPAR-
delta technology in all fields		 Galapagos is entitled to €770,000 in license fees, up to €27M (US$35M) in milestones, undisclosed milestone payments in Hillcrest equity and single-digit royalties on any resulting sales (2/1)
Immuno-
Biological
Laboratories
Co. Ltd.*		 Intellect
Neurosciences
Inc.* 		Intellect acquired rights to
two beta-amyloid-specific,
humanized monoclonal anti-bodies for
Alzheimer's disease		 IBL is eligible to receive milestone and royalty payments in the deal; it also got rights to certain antibody technology (1/11)
Inex
Pharmaceuticals
Corp. (Canada;
TSX:IEX)		 Alnylam
Pharmaceuticals
Inc. (ALNY)		 Alnylam got worldwide rights
to liposomal delivery technology for use with RNAi therapeutics; they also expanded existing deal on lipid-based delivery technology		 Inex also got certain options to develop its own RNAi therapeutics, and gained certain access to Alnylam technology for drug development; Inex gets $8M up front in stock or cash, $4M in R&D funding over two years, and up to $13M in milestone payments for each resulting product; it also will provide manufacturing services, and would get royalties on sales (1/9)
Insert
Therapeutics
Inc.*		 R&D Biopharma-
ceuticals GmbH*
(Germany)		 Collaboration to develop conjugates of tubulysin, a cancer compound using Insert's Cyclosert drug delivery system Agreement provides a research license and an option for an exclusive license to develop and commercialize tubulysinpolymer conjugates; R&D stands to receive up-front fees and research funding, as well as potential milestones and royalties (1/17)
Invitrogen
Corp. (IVGN)		 Progenitor Cell
Therapy LLC*		 Co-marketing and development deal to apply Invitrogen's media and cell separation technologies for cell product- ased applications Financial terms were not disclosed (1/22)
Invitrogen
Corp. (IVGN)		 Wave Biotech
LLC*		 Partnership to supply media-filled disposable bioreactors, specifically Invitrogen's GIBCO brand cell culture media products Wave Biotech provides a bioreactor system for customer use; financial terms were not disclosed (1/16)
In-Vivo Science
Inc.* and
CLEA Japan Inc.*		 Artemis
Pharmaceuticals
GmbH (Germany;
subsidiary of
Exelixis Inc.; EXEL)		 Partnership to generate, market and deliver genetically engineeredmouse models for the Japanese market The alliance combines Artemis' technology platform in mouse genetics and genomics with CLEA's and IVS's expertise in rodent breeding and distribution (1/29)
Laboratory Corp.
of America
Holdings
(NYSE:LH)		 ARCA Discovery
Inc.*		 Exclusive collaboration to develop a commercial genetic test to aid in the prescribing of bucindolol, a genetically- targeted heart failure drug in development by ARCA Financial terms were not disclosed (2/13)
Lentigen Corp.* Wave Biotech
LLC*		 Collaboration in which Wave Biotech will provide process and equipment expertise for Lentigen's manufacturing platform Financial terms were not disclosed (1/25)
Light
Sciences
LLC*		 Light
Sciences
Oncology Inc.*		 LSO purchased the assets of its former parent company, Light Sciences, through the issuance of common stock LSO now owns all Light Infusion Therapy technology, as well as other assets and subsidiaries of LS LLC (1/4)
Lipomics
Technologies
Inc.*		 Isis
Pharmaceuticals
Inc. (ISIS)		 Agreement to provide lipid-focused support of preclinical and clinical trial testing for various compounds to treat metabolic disease Lipomics will retain exclusive rights to develop diagnostic applications based on the data from the studies, while Isis will retain all therapeutic rights (2/14)
Medivir AB
(Sweden;
SSE:MVIRB)		 Presidio
Pharmaceuticals
Inc.*		 Presido got rights to the Phase II HIV agent alovudine (MIV-310), and to the preclinical antiviral MIV-410 Medivir gets equity in Presidio, along with milestone payments up to $75.25M and royalties on sales; it retained rights in the UK and Nordic countries, and has an option to gain rights in the rest of Europe (12/20)
MNL Pharma
Ltd.* (UK)		 VASTox plc
(UK; AIM:VOX)		 VASTox acquired a series of preclinical compounds and other technology and assets MNL had gone into administration in October; an inital payment of £0.24M (US$0.47M) was made to MNL (12/14)
Neuralstem
Inc. (OTC BB:
NRLS)		 Biomedical
Research
Models Inc.*		 BRMI got exclusive rights to develop Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes Neuralstem gets annual license fees, along with up to $38M in milestone payments per product, and royalties on resulting sales (1/11)
NitroMed Inc.
(NTMD)		 Elan Corp. plc
(Ireland;
NYSE:ELN)		 Exclusive worldwide license agreement to patents and technology that will be used to develop an extended- release formulation of BiDil NitroMed will pay Elan milestones and royalties on any product sales (2/14)
ProStrakan
Group plc
(UK:LSE:PSK)		 Galapagos NV
(Belgium;
Euronext:GLPG)		 Galapagos got an option to license oestradiol glucoside (E2G), a Phase IIa product for treating hot flashes The deal was made along with Galapagos' acquisition of ProStrakan subsidiary ProSkelia SASU (12/22)
Qualyst Inc.* InterMune Inc.
(ITMN)		 InterMune got rights to use Qualyst's B-Clear system in drug discovery operations Terms of the multiyear license deal were not disclosed (1/9)
Ryogen LLC* Invitrogen
Corp. (IVGN)		 Invitrogen got nonexclusive rights to technology on the Aminopeptidase P gene The gene codes for a protein believed to serve as a marker for a number of diseases; terms of the deal were not disclosed (1/9)
Seattle
Genetics Inc.
(SGEN)		 Genentech Inc.
(NYSE:DNA)		 Genentech got worldwide rights to SGI's SGN-40, a humanized monoclonal antibody in Phase I and II trials for blood cancers SGI gets $60M up front, and milestone payments that could exceed $800M, including $20M in committed funds over two years; SGI would get escalating double- digit royalties on sales, and retained a co-promotion option in the U.S. (1/8)
Seattle
Genetics Inc.
(SGEN)		 Agensys Inc.* Deal to use antibody-drug conjugate technology from SGI with Agensys antibodies to develop cancer drugs An initial target has been selected; they will co-fund development and would share equally any profits; Agensys has rights to develop drugs to three additional targets, for which SGI would be entitled to fees, milestones and royalties (1/8)
Sequenom
Inc. (SQNM)		 Qiagen NV
(the Netherlands;
QGEN)		 Deal to develop a preanalytical solution for small-molecule (fetal) DNA enrichment for prenatal diagnostics They will use Qiagen's preanalytical sample preparation technologies with Sequenom's capabilities in genetic analysis in the effort (1/8)
SmartGene Inc.*
(subsidiary of
SmartGene GmbH;
Switzerland)		 Laboratory
Corp.
of America
Holdings
(NYSE:LH)		 Collaboration to use LabCorp.'s technology and integrated web-based services to support more rapid and precise identification of bacterial and fungal pathogens Terms were not disclosed (2/20)
Stallergenes
SA* (France)		 Paladin Labs
Inc. (Canada;
TSX:PLB)		 Paladin got rights in Canada to Oralair, or allergen extract immunotherapy sublingual tablets The deal covers allergy products for grasses, birch and mites; they expect to seek approval of Oralair Grasses in 2007 (1/9)
Sunesis
Pharmaceuticals
Inc. (SNSS)		 SARcode Corp.* SARcode licensed Sunesis' LFA-1 inhibitor program, with which it intends to develop small-molecule drugs to treat inflammatory diseases Sunesis previously discontinued development of the program; it gets $0.25M up front and a $0.25M stake in SARcode, as well as up to $1M in license fees, $31M in milestone payments, and royalties on resulting sales (1/4)
Telik Inc. (TELK) SRI
International*		 Exclusive license agreement for SRI to conduct preclinical studies of a Telik drug candidate for multiple sclerosis and other auto-immune and inflammatory diseases The agreement relates to studies of C243, which isdesigned to help prevent leukocyte infiltration; Telik has an option to re-acquire C243 rights in the future (2/8)
TiGenix*
(Belgium)		 Fidia Advanced
Biopolymers
(Italy;
MI:FDA)		 Agreement to develop and commercialize biological implants to repair damaged and osteoarthritic joints The cell-based products for cartilage regeneration, combine TiGenix' Chondro-Celect product with FAB's Hyalograft C scaffold (1/31)**
Tikvah
Therapeutics
Inc.*		 Therapade
Technologies
LLC*		 Licensing agreement for worldwide rights to develop and commercialize D-cycloserine and related compounds for anxiety-related disorders Tikvah also will explore additional indications for D- cycloserine through its own research and development efforts (2/14)
Trellis
Bioscience Inc.*		 PDL BioPharma
Inc. (PDLI)		 Agreement to use Trellis' CellSpot technology to discover monoclonal antibodies directed at a PDL antigen Trellis will use its technology to screen large populations of antibody-producing cells developed by the companies and will select and deliver hybridomas to PDL for further development; PDL will hold rights to develop and commercialize any products, and Trellis is entitled to an up-front fee, milestone payments and royalties (1/16)
Trigen Ltd.* Millennium
Pharmaceuticals
Inc. (MLNM)		 Exclusive worldwide license agreement for patents covering glycoprotein VI, a target receptor in regulating platelet adhesion during thrombosis Millennium will receive up-front payments, payments for development and regulatory milestones and royalties (1/23)
Zyentia Ltd.*
(UK)		 Potentia
Pharmaceuticals
Inc.*		 Potentia gained access to Zyentia's AggreSolve platform to characterize some of its compounds Terms of the research collaboration were not disclosed (1/8)
Notes:
* Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International.
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.
AIM = Alternative Investment Market; BE = Berlin Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; MI = Milan Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.